An article authored by Aquarius was published today on the British In Vitro Diagnostics Association (BIVDA) website. The article commissioned jointly by BIVDA and Innovate UK suggests that the NHS could save over £6.9 billion in 5 years by making better use of diagnostic tests already on the market. These savings could have a huge impact in reducing the annual NHS shortfall, which is expected to be £20 billion by 2022.
The winter flu season brings added pressure to emergency and acute hospital services. In the UK, children and infants account for more than a third of flu related hospital admissions since flu and respiratory syncytial viruses (RSV) can be particularly severe in children, particularly those with existing conditions such as asthma.
In our recent paper published, we report the results of a real-world evaluation conducted in a busy children’s hospital in central London. We assessed the impact and economic benefits of using a 90-minute point-of-care (POC) assay to test for influenza and RSV in children and infants admitted to hospital. This was done by comparing data collected from an acute paediatric ward during one flu season, when standard laboratory testing was used, with data collected from the same ward in the subsequent flu season, when the POC test was in use.
In the latest episode of the BBC’s show, “Trust me, I’m a Doctor”, an innovative new product called Magseed is being trialled to improve surgery for women with breast cancer. A tiny magnetic seed is being used to transform how cancerous tissue is localised so that it can be removed, rather than using traditional guide wires. This helps the surgeons pinpoint exactly where they need to operate, and which angle is the best to approach the tumour. Much smaller tumours are currently being detected through the breast cancer screening programme, which are more difficult to find during surgery using guide wires.
Aquarius Population Health recently worked with the Applied Diagnostic Research & Evaluation Unit (ADREU) at St. Georges, University of London, to assess the cost-effectiveness of six hypothetical strategies for using antimicrobial resistance point-of-care testing to guide the treatment of gonorrhoea. Our findings were presented at the STI & HIV World Congress in Rio de Janeiro, Brazil. [Wednesday 12th July, Session 15: STI/HIV testing and management].
We were a collaborator on a recent Innovate UK-funded SBRI project with Atlas Genetics and the Applied Diagnostic Research and Evaluation Unit at St George’s University of London. In this project, our team compared the overall costs, patient benefits and cost-effectiveness of three different multi-pathogen point-of-care testing strategies with the current strategy of microscopy and lab-based testing.
Personalised medicine is an emerging field that brings exciting changes to patient care. So, what exactly is personalised medicine and what are its benefits?
In the past, various terms have been used interchangeably: ‘stratified medicine’, ‘personalised medicine’ and ‘precision medicine’. These terms refer to data driven medicine, in which data can be a patient’s genetic makeup, molecular data or disposition to respond to therapy. These data allow for a targeted approach to prevention, diagnosis and treatment using technologies such as genomic medicine, diagnostic tests, predictive data analytics or real-time patient monitoring.
January has been a busy month for Aquarius Population Health, and our team members have spoken at and attended several fascinating events. Our Managing Director, Dr Elisabeth Adams, presented at the invitation-only DHACA Day XI on the 18th January. Drawing from her extensive experience delivering health economic projects, Elisabeth provided key insights on how patient pathway mapping and economic evaluation help demonstrate the value of digital health products. Digital Health and Care Alliance (DHACA) is a non-for-profit organisation dedicated to sharing knowledge and advancing digital healthcare systems in the UK and Europe.